Dernières nouvelles pour Innate Pharma (NASDAQ:IPHA) Stock

Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Innate Pharma S.A. - American Depositary Shares

Innate Pharma SA

Deutsche Bank AG Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) shares are trading lower on Monday. A new Bloomberg report suggests a shareholder is preparing to sell 16 million shares, valued at approximately $279 million, of the German lender. Here&#8217;s<a href="https://www.benzinga.com/trading-ideas/24/09/41095830/3-stocks-to-consider-from-the-prospering-foreign-banks-industry"> what you need to know.</a>
What To Know: <a href="https://www.bloomberg.com/news/articles/2024-10-14/deutsche-bank-shareholder-is-looking-to-sell-279-million-stake?srnd=homepage-americas&amp;sref=TBDibEcD">According to Bloomberg</a>, a single shareholder is offering to sell around 16 million shares, which is expected to price at 16.01 euros ($17.46) per share. The transaction could generate roughly 256 million euros ($279 million) in gross proceeds for the seller. The deal is being arranged by<a href="https://www.benzinga.com/news/earnings/24/10/41318123/goldman-sachs-gears-up-for-q3-reveal-will-its-earnings-shine-like-other-major-banks"> Goldman Sachs</a>, though Deutsche Bank has declined to comment.
This development comes amid a broader trend of sell-offs in European companies, as stockholders aim to capitalize on high stock prices. Since early September, nearly $11 billion worth of deals have been priced, with banking institutions like Commerzbank, National Bank of Greece and Santander Bank Polska also seeing significant shareholder exits.
Why It Matters: The shareholder's decision to sell may suggest an opportunity to lock in profits as the bank's stock price climbs. This sale occurs just ahead of the bank's third-quarter earnings release, scheduled for Oct. 23, before the market opens. Analysts expect the bank to report estimated earnings per share of 58 cents and revenue of $7.820 billion.
DB Price Action: Deutsche Bank shares were down by 1.80% at $17.44 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="535" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14155445/DB-1024x535.png" alt="" class="wp-image-594716" style="width:462px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14155445/DB-1024x535.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14155445/DB-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14155445/DB-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14155445/DB.png 1432w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41320155/bitcoin-ethereum-dogecoin-pick-up-steam-btc-entering-fomo-zone-trader-touts">Bitcoin, Ethereum, Dogecoin Pick Up Steam: &#8216;BTC Entering FOMO Zone,&#8217; Trader Touts</a></li>
</ul>
Image Created Via Midjourney.

News

Movers

Trading Ideas

What's Going On With Deutsche Bank Stock Monday?

Whether it&#39;s through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you&#39;re an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company&#39;s earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases.
<h2>Unum in Focus</h2>
Unum (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unm#NYSE">UNM</a>) is headquartered in Chattanooga, and is in the Finance sector. The stock has seen a price change of 38.72% since the start of the year. The insurance company is currently shelling out a dividend of $0.42 per share, with a dividend yield of 2.68%. This compares to the Insurance - Accident and Health industry&#39;s yield of 1.74% and the S&amp;P 500&#39;s yield of 1.5%.
Taking a look at the company&#39;s dividend growth, its current annualized dividend of $1.68 is up 20.9% from last year. Over the last 5 years, Unum has increased its dividend 4 times on a year-over-year basis for an average annual increase of 7.59%. Future dividend growth will depend on earnings growth as well as payout ratio, which is the proportion of a company&#39;s annual earnings per share that it pays out as a dividend. Right now, Unum&#39;s payout ratio is 18%, which means it paid out 18% of its trailing 12-month EPS as dividend.
UNM is expecting earnings to expand this fiscal year as well. The Zacks Consensus Estimate for 2024 is $8.49 per share, with earnings expected to increase 10.84% from the year ago period.
<h2>Bottom Line</h2>
Investors like dividends for many reasons; they greatly improve stock investing profits, decrease overall portfolio risk, and carry tax advantages, among others. However, not all companies offer a quarterly payout.
Big, established firms that have more secure profits are often seen as the best dividend options, but it&#39;s fairly uncommon to see high-growth businesses or tech start-ups offer their stockholders a dividend. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, UNM is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of 3 (Hold).
<a href="https://www.zacks.com/stock/news/2350098/why-unum-unm-is-a-great-dividend-stock-right-now?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-2350098">To read this article on Zacks.com click here.</a>

Earnings

Large Cap

Dividends

Markets

Analyst Ratings

Insurance

Why Unum is a Great Dividend Stock Right Now

Investors in Canadian Natural Resources Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cnq#NYSE">CNQ</a>) need to pay close attention to the stock based on moves in the options market lately. That is because the Nov. 15, 2024 $60.00 Call had some of the highest implied volatility of all equity options today.
<h2>What is Implied Volatility?</h2>
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
<h2>What do the Analysts Think?</h2>
Clearly, options traders are pricing in a big move for Canadian Natural Resources shares, but what is the fundamental picture for the company? Currently, Canadian Natural Resources is a Zacks Rank #3 (Hold) in the Oil and Gas - Exploration and Production - Canadian industry that ranks in the Bottom 27% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while three analysts have revised their estimates downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from 82 cents per share to 71 cents in that period.
Given the way analysts feel about Canadian Natural Resources right now, this huge implied volatility could mean there&#39;s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
<a href="https://www.zacks.com/stock/news/2350099/implied-volatility-surging-for-canadian-natural-resources-cnq-stock-options?cid=CS-BENZ-FT-tale_of_the_tape|options-2350099">To read this article on Zacks.com click here.</a>

Options

Implied Volatility Surging for Canadian Natural Resources Stock Options

BLND

Blend Enters Partnership With PenFed Credit Union To Enhance Home Lending Operations

With the Dow Jones Industrial Average at all-time highs, the earnings report from UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) on Tuesday before the market open could be <a href="https://www.benzinga.com/earnings">of particular interest.</a>
Earnings Estimates: Analysts expect UnitedHealth to report third-quarter revenue of $99.28 billion, up from $92.36 billion in last year's third quarter, according to data<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101424&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a>
The company has beaten analyst estimates for revenue in nine of the last 10 quarters, with the most recently <a href="https://www.benzinga.com/news/earnings/24/07/39790051/unitedhealth-q2-earnings-revenue-and-eps-beat-lifts-cyberattack-impact-estimate-reaffirms-profit-ou">reported second-quarter</a> results the lone miss.
Analysts expect the company to report third-quarter earnings per share of $7.00, up from $6.56 in last year's third quarter. The company has beaten analyst estimates for earnings per share in nine of the last 10 quarters, with the lone miss coming in the second quarter.
Read Also: <a href="https://www.benzinga.com/news/large-cap/24/10/41256923/cvs-unitedhealth-request-ftc-chair-recusal-amid-ongoing-pharmacy-benefit-managers-lawsuit">CVS, UnitedHealth Request FTC Chair Recusal Amid Ongoing Pharmacy Benefit Managers Lawsuit</a>
Why It's Important: UnitedHealth's second quarter results were significantly impacted by a cyberattack against the company's billing and payments business, which led to misses in earnings and revenue compared to analyst estimates.
Third-quarter estimates expect the company to post growth on a year-over-year basis for both segments and the stock could be one of the most watched for the week with earnings season in full swing.
With a share price over $600, UnitedHealth is currently the largest weighting in the price-weighted Dow Jones Industrial Average at around 9.5%.
"Look for United Healthcare to move markets as it is the largest component in the Dow Jones Industrial Average," Freedom Capital Markets Chief Global Strategist Jay Woods said in his weekly <a href="https://jaywoods.substack.com/">newsletter</a>. &nbsp;
The earnings report comes with the Dow Jones Industrial Average<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41319060/s-p-500-extends-record-highs-dow-breaks-43-000-ahead-of-pivotal-earnings-week-bitco"> hitting new all-time highs </a>of 43,111.45 on Monday. The SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), which tracks the index, was up 0.5% to $430.89 on Monday.
Recent<a href="https://www.benzinga.com/quote/UNH/analyst-ratings"> analyst ratings for </a>UnitedHealth include Cantor Fitzgerald reiterating an Overweight rating with a $591 price target and KeyBanc initiating the stock with an Overweight rating with a $675 price target.
UNH Price Action: UnitedHealth stock was up 1.2% to $605.40 on Monday, versus a 52-week trading range of $436.38 to $607.90. UnitedHealth stock is up 12.5% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/24/09/40965040/unitedhealth-vs-cvs-vs-cigna-which-health-stock-will-beat-the-ftcs-regulatory-heat">UnitedHealth Vs. CVS Vs. Cigna: Which Health Stock Will Beat The FTC&#8217;s Regulatory Heat?</a></li>
</ul>
Photo: JHVEPhoto/Shutterstock.com

Previews

UnitedHealth Group Q3 Earnings Preview: Dow Jones Industrial Average Stock Could 'Move Markets' Tuesday

Management

JYNT

The Joint Corp Appoints Sanjiv Razdan As Its President And CEO, Effective Today; Peter Holt Resigns

September production decreased by approximately&nbsp;2%&nbsp;month over month from August (19.7 BTC mined) due to the increase in the bitcoin difficulty level which peaked at 92.67 in September vs. 90.67 in August 2024.
&nbsp;

GRYP

Gryphon Digital Mining Releases Operational Update For September; Expect To Have Generated Revenues Of $1.16M For September, Based On An Average Bitcoin Price Of $60,286

Investors interested in Furniture stocks are likely familiar with Flexsteel Industries (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flxs#NASDAQ">FLXS</a>) and SharkNinja, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sn#NYSE">SN</a>). But which of these two stocks presents investors with the better value opportunity right now? Let&#39;s take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Flexsteel Industries and SharkNinja, Inc. are both sporting a Zacks Rank of # 1 (Strong Buy) right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that both of these companies have improving earnings outlooks. But this is just one piece of the puzzle for value investors.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
FLXS currently has a forward P/E ratio of 13.79, while SN has a forward P/E of 25.42. We also note that FLXS has a PEG ratio of 1.15. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company&#39;s expected earnings growth rate. SN currently has a PEG ratio of 1.72.
Another notable valuation metric for FLXS is its P/B ratio of 1.42. Investors use the P/B ratio to look at a stock&#39;s market value versus its book value, which is defined as total assets minus total liabilities. By comparison, SN has a P/B of 9.12.
Based on these metrics and many more, FLXS holds a Value grade of A, while SN has a Value grade of D.
Both FLXS and SN are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that FLXS is the superior value option right now.
<a href="https://www.zacks.com/stock/news/2350085/flxs-or-sn-which-is-the-better-value-stock-right-now?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-2350085">To read this article on Zacks.com click here.</a>

Small Cap

Tech

FLXS

FLXS or SN: Which Is the Better Value Stock Right Now?

SGHT

Sight Sciences Reports Publication Of New Study Titled, Impact Of TearCare On Reading Speed In Patients With Dry Eye Disease In The Peer-reviewed Journal Clinical Ophthalmology

WIIM

PHX Minerals shares are trading higher after the company announced WhiteHawk Energy sent a letter regarding its acquisition proposal.

Blink is offering a solution for former Enel X and JuiceBox customers to power up their EV charging with Blink.&nbsp;
All customers need to do is prepare their site, and Blink will handle the rest. Additionally, if you already have a JuiceBox charging station but need an upgrade, Blink will swap it out for free.

BLNK

Blink Charging Steps In To Support EV Charging Station Hosts Affected By Enel X's Recent Decision To Close Its North American Operations

Investors interested in stocks from the Financial - Investment Management sector have probably already heard of Victory Capital Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vctr#NASDAQ">VCTR</a>) and SEI Investments (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/seic#NASDAQ">SEIC</a>). But which of these two stocks offers value investors a better bang for their buck right now? We&#39;ll need to take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Victory Capital Holdings and SEI Investments are both sporting a Zacks Rank of # 2 (Buy) right now. Investors should feel comfortable knowing that both of these stocks have an improving earnings outlook since the Zacks Rank favors companies that have witnessed positive analyst estimate revisions. However, value investors will care about much more than just this.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
VCTR currently has a forward P/E ratio of 11.12, while SEIC has a forward P/E of 16.52. We also note that VCTR has a PEG ratio of 0.61. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company&#39;s expected earnings growth rate. SEIC currently has a PEG ratio of 1.38.
Another notable valuation metric for VCTR is its P/B ratio of 3.36. The P/B ratio pits a stock&#39;s market value against its book value, which is defined as total assets minus total liabilities. For comparison, SEIC has a P/B of 4.05.
These metrics, and several others, help VCTR earn a Value grade of B, while SEIC has been given a Value grade of C.
Both VCTR and SEIC are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that VCTR is the superior value option right now.
<a href="https://www.zacks.com/stock/news/2350084/vctr-vs-seic-which-stock-is-the-better-value-option?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-2350084">To read this article on Zacks.com click here.</a>

Mid Cap

SEIC

VCTR

VCTR vs. SEIC: Which Stock Is the Better Value Option?

Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) and the Department of Culture and Tourism – Abu Dhabi announced that they will work together to bring the world's second Sphere to Abu Dhabi, United Arab Emirates. This next-generation entertainment medium is expected to be a landmark addition to this premier international capital city, elevating the entertainment offerings for residents and visitors alike.

Global

SPHR

Sphere Entertainment And The Department Of Culture And Tourism – Abu Dhabi Announce Plans To Make Abu Dhabi Next Sphere Venue Location

MDAI

Spectral AI shares are trading higher after the company announced it named its founder Dr. J. Michael DiMaio as the Chairman.

Spectral AI Names Founder Dr. J. Michael DiMaio As Chairman

<a href="https://pr.report/3i0a">Gryphon Digital Mining</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) ("Gryphon" or the "Company"), a bitcoin mining company that is focused on low-cost, efficient operations, has released its unaudited operational update for September 2024.
Key September 2024 highlights:
Steve Gutterman Named as Chief Executive Officer, Jimmy Vaipoulos as Chairman and Sim Salzman to continue as Chief Financial Officer
+500 MW power pipeline: Gryphon continues to evaluate a pipeline of similar low-cost opportunities for potentially +500 MW
Improved Hashrate: Monthly average hashrate of 920 PH/s, a 4% increase over August 2024
Bitcoin Production: Expect to have produced approximately 19.31 bitcoin
Projected approximately $1.16 million in value based on an average bitcoin price for the month of $60,286
High Uptime: 98.7% mining fleet average up time in September following 97.3% in August due to maintenance
Sustainable Operations: Scope 1 and Scope 21 operations at our Northeastern U.S. operations continue to be 100% electrified by zero-carbon emitting hydro power

Gryphon Digital Mining Announces September Operational Update; Expect To Have Produced ~19.31 Bitcoin

The letter includes details of the extensive efforts WhiteHawk has made over the past 18 months to engage with PHX to maximize value for stockholders through a transaction.
Urges the PHX Board of Directors to engage with WhiteHawk to pursue and complete a transaction following unwillingness to engage over the past 18 months

WhiteHawk Energy Sends Letter To PHX Minerals Chairman Mark Behrman With Respect To Its $4.00 Per Share Proposal

<a href="https://patentcenter.uspto.gov/applications/17677698/ifw/docs" title="https://patentcenter.uspto.gov/applications/17677698/ifw/docs">https://patentcenter.uspto.gov/applications/17677698/ifw/docs</a>

Biotech

General

HOTH

Hoth Therapeutics Has Received A Notice Of Allowance For Its U.S. Patent Application 17/677,698 Titled "USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE".

Former Congressman Joe Garcia, who represented Florida's 26th congressional district, has voiced strong support for the cannabis legalization measure, known as <a href="https://www.benzinga.com/markets/cannabis/24/04/38034138/florida-supreme-court-approves-cannabis-legalization-proposal-for-november-election-in-blow-to-d" target="_blank" rel="noreferrer noopener">Amendment 3</a>, that will appear on the ballot in the <a href="https://www.benzinga.com/topic/2024-election">upcoming November elections</a>
"One of the most compelling reasons to support Amendment 3 is the growing body of research that suggests marijuana acts as an exit substance, not a gateway drug," said Garcia in a <a href="https://www.miamiherald.com/opinion/article293689854.html">Miami Herald</a> opinion piece. "Contrary to outdated beliefs, numerous studies have shown that marijuana can help individuals reduce their dependence on more harmful substances, including prescription opioids."
He pointed out that the illicit market poses risks, including reports of marijuana being laced with dangerous substances like <a href="https://www.benzinga.com/topic/fentanyl">fentanyl</a>. By regulating the market, Florida could ensure that consumers have access to safe, lab-tested products, he said.
Garcia also addressed concerns about teenage cannabis use. "Research indicates that in states where marijuana is legal, teen use rates have actually declined. This is likely due to the stringent regulations and safeguards that come with legalization, making it more difficult for underage individuals to access marijuana."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41250277/miami-herald-endorses-florida-cannabis-legalization-highlights-failed-drug-war-revenue-potential">Miami Herald Endorses Florida Cannabis Legalization, Highlights Failed Drug War, Revenue Potential</a>
<h2 class="wp-block-heading">And Then There's The Money</h2>
Estimates suggest that legalized marijuana could generate up to $431 million annually in new tax revenue in Florida.
"This influx of funds could be directed toward essential public services such as education, healthcare and infrastructure. Imagine the positive impact on our schools, hospitals and roads with this additional revenue stream. It's an opportunity to invest in our future and improve the quality of life for all Floridians," Garcia wrote.
This new source of income, he said, could have a transformative impact on the state.
"We have fewer individual freedoms and we are passing up millions in tax revenue, tourism dollars and market growth that will create new jobs right here in Florida. Amendment 3 is not just about legalizing marijuana; it's about adopting a sensible, evidence-based approach to drug policy."
Garcia is a paid advisor for the organization <a href="https://drupal-cloudfront.benzinga.com/topic/smart-and-safe-florida" target="_blank" rel="noreferrer noopener">Smart and Safe Florida</a>, which helped get Amendment 3 on the ballot.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41303141/fact-check-desantis-why-floridas-weed-legalization-does-not-mean-smoking-in-schools">Fact-Check DeSantis: Why Florida&#8217;s Weed Legalization Does Not Mean Smoking In Schools</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Cannabis

Regulations

Politics

Legal

Florida Cannabis Legalization Gains Support From Former Congressman, Citing Economic Growth, Public Health

Editor&#8217;s note: This article was updated to correctly state the title of the CCO and co-founder of Cornbread Hemp.
A California judge has denied a temporary restraining order (TRO) filed by national hemp advocates and businesses, including <a href="https://www.benzinga.com/markets/cannabis/24/10/41196739/cheech-and-chong-cannabis-company-hemp-roundtable-petition-court-to-stop-gov-newsoms-controversi">Cheech and Chong's Global Holdings</a>, aimed at blocking the state's controversial ban on hemp products with detectable levels of THC. 
The TRO, which was requested as part of a lawsuit filed last month by the U.S. Hemp Roundtable and several hemp companies, sought to halt the enforcement of the new regulations until the case could be fully heard. 
However, the judge sided with the state and Gov. Gavin Newsom, allowing the ban to remain in place.
<h3 class="wp-block-heading">Emergency Regulations Banning Hemp</h3>
The <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">emergency regulations</a>, which went into effect on September 23, prohibit the sale of consumable hemp products with any detectable delta-9 THC or intoxicating cannabinoids like delta-8 THC in California. 
These regulations also limit hemp products to five servings per package and restrict sales to individuals aged 21 and over. 
Hemp advocates argue that this will severely impact the industry, especially businesses producing non-intoxicating hemp products that provide therapeutic benefits to consumers.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41124583/californias-new-hemp-rules-could-reshape-cannabis-a-different-set-of-rules-in-every-state">California&#8217;s New Hemp Rules Could Reshape Cannabis: &#8216;A Different Set Of Rules In Every State&#8217;</a>
<h3 class="wp-block-heading">Industry Reacts</h3>
The ruling prompted strong reactions. 
&#8220;Today, a judge sided against common sense and in favor of Gov. Newsom. The judge's ruling to deny a temporary restraining order against Newsom's hemp products ban announces that Californians will lose access to USDA-certified organic hemp products in retail stores across the state,&#8221; Jim Higdon, CCO and co-founder of <a href="https://www.benzinga.com/markets/cannabis/24/09/40833963/expert-calls-for-a-united-hemp-and-cannabis-front-industries-should-collaborate-and-push-for-fed">Cornbread Hemp </a>and a member of the U.S. Hemp Roundtable, told Benzinga Cannabis in an email.
&#8220;At a time when the California cannabis dispensary system is undergoing a credibility crisis due to pesticide contamination, the governor has made it much more difficult for Californians to access the only cannabis products that consumers can be certain are free of pesticides – USDA-certified organic hemp products with third-party lab tests,&#8221; Higdon said.
The legal battle is set to continue, as the case moves forward, with the hemp industry determined to challenge the ban's legality in court.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">Gov. Newsom&#8217;s Hemp Ban Goes Into Effect: Consequences For Industry, Investors, Patients</a></li>
</ul>
Cover: AI Generated Image

Government

California Judge Rules Gov. Newsom's Hemp Ban Stands Despite Industry Pushback (Corrected)

Kepler Capital analyst Justine Telliez maintained a Hold rating on Innate Pharma SA (IPHYF – Research Report) on September 9 and set a price target...

Kepler Capital  Sticks to Its Hold Rating for Innate Pharma SA (IPHYF)

Innate Pharma GAAP EPS of -€0.31, revenue of €12.35M

Innate Pharma S.A. (IPHA) Q2 2024 Earnings Call Transcript

Goldman Sachs analyst Rajan Sharma has maintained their neutral stance on IPHYF stock, giving a Hold rating on September 9. Rajan Sharma has given ...

Hold Rating on Innate Pharma SA Amid FDA Discussions and Strategic Uncertainties

In a report released on September 12, Justine Telliez from Kepler Capital maintained a Hold rating on Innate Pharma SA (IPHYF – Research Report), w...

Kepler Capital  Reaffirms Their Hold Rating on Innate Pharma SA (IPHYF)

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Innate Pharma (IPHA – Research Report) on September 13 and set a price target of $5.00....

Innate Pharma (IPHA) Receives a Buy from Evercore ISI

Innate gets FDA clearance for Phase 1 study for IPH4502 ADC candidate

In a report released on September 26, Justine Telliez from Kepler Capital maintained a Hold rating on Innate Pharma SA (IPHYF – Research Report), w...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Innate Pharma (IPHA – Research Report) on October 4. The company's shares close...

Comments

Innate Pharma

Actualités

Dernières nouvelles pour Innate Pharma (NASDAQ:IPHA) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL